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Pancreas is a doubled-entity organ, with both an exocrine and an endocrine component, reciprocally interacting in a composed
system whose function is relevant for digestion, absorption, and homeostasis of nutrients. Thus, it is not surprising that disorders
of the exocrine pancreas also affect the endocrine system and vice versa. It is well-known that patients with chronic pancreatitis
develop a peculiar form of diabetes (type III), caused by destruction and fibrotic injury of islet cells. However, less is known on
the influence of diabetes on pancreatic exocrine function. Pancreatic exocrine insufficiency (PEI) has been reported to be common
in diabetics, with a prevalence widely ranging, in different studies, in both type I (25–74%) and type II (28–54%) diabetes. A long
disease duration, high insulin requirement, and poor glycemic control seem to be risk factors for PEI occurrence. The impact of
pancreatic exocrine replacement therapy on glycemic, insulin, and incretins profiles has not been fully elucidated. The present
paper is aimed at reviewing published studies investigating the prevalence of PEI in diabetic patients and factors associated with its
occurrence.
1. Introduction
Pancreas is a doubled-entity organ, with both an exocrine and
an endocrine component, reciprocally interacting and closely
cooperating for the digestion, absorption, and metabolism of
oral nutrients [1].
Thanks to its lobulated tubulo-alveolar-acinar structure,
endocrine islet cells secrete their hormones in the insulo-
acinar portal vascular pathway, thus regulating and condi-
tioning ductal and acinar cell exocrine activities [2].
It has been recently demonstrated that the rise of insulin
and other pancreatic islet peptides (amyline, C-peptide, and
urocortin-III), following the postprandial glucose rise, stimu-
lates the exocrine pancreatic function [3]. On the other hand,
the increase of glucagon during fasting depresses pancreatic
enzyme and juice secretion.
Ductal and acinar cells, in turn, affect the physiology of
endocrine islet cells through cytokines and growth factor
secretion [2, 3].
Furthermore, the endocrine cells disseminated in the
small bowel secrete two peptide hormones, glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic hor-
mone (GIP), known as incretins, that are released soon after
lipid and carbohydrate ingestion, thus stimulating a strong
insulinic production. A deregulation of incretin secretion is
one of the causes of the altered insulinic response in type II
diabetes [4].
With regard to chronic pancreatitis patients, it is well
described that they may suffer from a peculiar form of
diabetes (type III diabetes), characterized by the destruction
of islet cells by inflammatory and fibrotic injury. Type III
diabetes differs from type I diabetes as the damage of
pancreatic islets is not limited to insulin secreting beta cells
but is more diffused as it also affects glucagon and pancreatic
polypeptide secreting alpha and PP cells. In addition to this,
in type III diabetes the malabsorption of nutrients due to
pancreatic exocrine insufficiency (PEI) results in impaired
incretin secretion with consequently diminished insulin
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release. Furthermore, as suggested by the 2012 PancreasFest
recommendations, a quote of type III diabetes patients may
also have preexisting risk factors for type II diabetes (e.g.,
insulin resistance, obesity, or dietary habits) that further
complicate the optimal regulation of glucose metabolism
resulting in a severe disease with large swings in blood sugar
that are hardly controlled [5].
On the other hand, less is known on the influence of
diabetes on pancreatic exocrine function.
As the prevalence of diabetes in the general population is
much higher than that of chronic pancreatitis, this relation-
ship is potentially of great clinical relevance.
In the sixties, a few pioneering studies investigated exo-
crine pancreatic function in small series of diabetic patients,
throughout direct duodenal juice collection (secretin
cerulein test or SCT) and reported changes in both output
and HCO
3
concentrations [6–8].
More recently, thanks also to the availability of a nonin-
vasive test for pancreatic exocrine function, such as measure-
ment of fecal elastase, several studies aimed at investigating
the prevalence of PEI in large cohorts of diabetic patients.
The present paper is aimed at reviewing findings of pub-
lished studies investigating the prevalence of PEI in diabetic
patients and possible risk factors and mechanisms associated
with its occurrence and severity. The cases of patients with
type I and type II diabetes will be discussed separately, in view
of possible different features and pathogenic mechanisms.
2. Pancreatic Exocrine Insufficiency in
Type I Diabetes
Abnormalities in histological features and imaging (MRI, CT,
and ultrasound) of the pancreas of diabetic patients have
been reported, as well as atrophy, fibrosis, changes in size,
and morphology; several and various hypotheses have been
proposed to explain these phenomena implicated in PEI
occurrence in diabetics [9, 22–25].
The damage of the exocrine cells in type I diabetes
is most likely multifactorial, with a number of possible
causes: (a) the lack of the trophic action of insulin (and
possibly of glucagon and somatostatin) on acinar cells; (b)
an involvement of the exocrine tissue in the autoimmune
destruction of islet cells; (c) autonomic diabetic neuropathy
leading to enteropancreatic reflex impairment; (d) hypoxic
sufferance of exocrine tissue due to microvascular damage
[26, 27].
In this view, type I diabetes, which is linked to a primary
autoimmune process and is characterized by early occur-
rence, severe insulin deficiency, and long standing disease,
with a high rate of neural and vascular complications, seems
to be more frequently associated with PEI than type II.
PEI seems to occur early in type I diabetes patients, and 2
studies assessing fecal elastase concentrations in children and
young patients, ranging from 2 to 25 years of age, detected
severe (defined by a cut-off of fecal elastase <100𝜇g/g) to
moderate PEI (elastase <200𝜇g/g) in 10% to 45% of screened
subjects [28, 29].
In adult series of type I diabetes patients, the prevalence
of both severe (10–30%) and moderate (22–56%) PEI seems
higher than in children, possibly suggesting that exocrine
pancreatic function decreases in parallel with the duration of
disease and the increase in insulin requirement. The largest
study [10] investigating risk factors for PEI occurrence in 195
type I diabetes patients demonstrated a strong association
between PEI and disease duration, but these results were not
confirmed in other settings and no association with insulin
requirement or elevatedHbA1cwas observed.However, these
latter studies had several limitations, such as a smaller num-
ber of subjects included, not well-defined enrollment criteria,
and poor investigation of risk factors for PEI occurrence.
Studies evaluating pancreatic exocrine function in adult type
I diabetes patients are summarized in Table 1 [9–15].
3. Pancreatic Exocrine Insufficiency in
Type II Diabetes
Physiopathologicalmechanism involved in PEI occurrence in
type II diabetes seems to be similar to that reported above
for type I diabetes. In particular, in these subjects, with-
out autoimmune damage and insulin deficiency, autonomic
neuropathy and microvascular damage may play a key role
in inducing pancreatic atrophy and fibrosis. Hayden and
colleagues observed that type II diabetes human and rodent
pancreas specimens show a loss of desmosomes and adherens
junctions between islet and acinar cells, due to fibrosis and
remodeling of the islet-acinar interface, that may result in an
impaired function [3].
Regarding PEI prevalence in type II diabetes more data
are available, although these are somehow more heteroge-
neous. Studies evaluating pancreatic exocrine function in
adult patients with type II diabetes are summarized in Table 2
[10, 12, 13, 15–21].
In the largest prospective study, performed on 1231
diabetic patients,Hardt and colleagues demonstrated a preva-
lence of PEI of 35% in 697 patients with type II diabetes.
However, the observed correlationswith disease duration and
insulin therapy in the general population of 1231 subjects were
not confirmed in the subgroup analysis of type II diabetes
patients. Notably, this study did not specifically exclude cases
with previous history of pancreatic disease, thus leading to a
possible bias [16].
Subsequent studies, enrolling a smaller number of
patients, confirmed a prevalence of PEI of about 30–40% in
type II diabetes. Although these results are often heteroge-
neous, most studies concord that the need of insulin therapy
is associated with a higher prevalence and with the severity of
PEI [10, 13, 15–21].
Early onset of type II diabetes and long disease duration
as well as poor glycemic control (expressed in particular as
elevated HbA1c) seem to be risk factors for the occurrence
and severity of PEI, although their role has not been con-
firmed in all studies and results were not always statistically
significant [10, 13, 15–21]. This supports the hypothesis that
a long, complicated type II diabetes, with a higher degree
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of microvascular damage, pancreatic fibrosis, and autonomic
neuropathy, ismore probably associatedwith PEI occurrence.
Interestingly, in most reports an elevated BMI seems to
be a protective factor for the occurrence of PEI occurrence.
However, this is most likely a bias, as patients with severe PEI
would showmalabsorption andmalnutrition and consequent
reduced BMI [10, 13, 15, 17–21].
4. Conclusions
The reciprocal relationship between the endocrine and
exocrine pancreatic function is an interesting and relatively
poorly investigated area of research in which many ques-
tions still remain unanswered. Most studies investigating
the prevalence of PEI in both type I and type II carry
several limitations (summarized in Tables 1 and 2). All these
mentioned studies have a “cross-sectional” design, and they
only evaluated the prevalence of PEI and not its incidence
over time in the course of the disease.One study prospectively
evaluated PEI with SCT, although during a short and not
standardized follow-up period and only in 17 type I diabetes
patients. In contrast with previous observations, this latter
study, with all the above mentioned limitations, observed
no changes in the exocrine pancreatic function during the
follow-up period [30].
The reported prevalence of PEI observed in type I (25–
74%) and type II (28–54%) diabetes in different studies
assessing PEI with fecal elastase measurement is also highly
variable. This heterogeneous prevalence could be due to
the low sensibility of fecal elastase, as reported by Hahn
and colleagues in a small series of type I diabetes patients,
who underwent both direct and indirect pancreatic function
tests [14]. A recent study reported that a noninvasive 13C-
Mixed Triglyceride Breath Test (C-MTGT) for evaluation of
pancreatic exocrine function can detectmild tomoderate PEI
in diabetes mellitus. However, the specificity of C-MTGT,
compared to direct SCT, is low in these patients, probably
because nonpancreatic mechanisms contribute to decrease
intestinal lipolysis [31]. To better assess PEI prevalence in
diabetic patients, future studies should also take into account
the dilution of elastase enzyme in stools during diarrhoea,
which is, irrespectively to PEI, a symptom often present
in diabetic subjects because of bacterial overgrowth and
diabetes-induced vascular or neuropathic complications [14,
31].
As regards the aetiology of PEI, a long duration of
disease, high insulin requirement, and poor glycemic control,
expression of more severe disease seems to be associated
with PEI occurrence and severity. In type II diabetes, a more
severe form of disease is more frequently associated with
systemic complications such as autonomic neuropathy and
microvascular damage, determining fibrosis and atrophy of
the pancreas, and loss of communication in the islet-acinar-
ductal axis and gastroenteropancreatic system.
In type I diabetes, the primary reduction of insulin levels
due to the autoimmune mediated damage of islet cells results
in a decreased trophic action on the exocrine cells.
This combination of multiple factors may explain the
observed higher prevalence of PEI observed in type I com-
pared to type II diabetes (about 60% versus 30% of cases).
However, the mechanisms causing PEI in diabetes still need
to be elucidated.
Furthermore, it is unclear which diabetic patients would
benefit from screening for PEI in clinical practice, and
there are very limited data regarding the possible impact of
pancreatic enzyme replacement therapy (PERT) on diabetic
subjects with PEI.
In a small series of 8 patients affected by chronic pancre-
atitis with PEI, half of them with type III Diabetes, Knop et
al. evaluated the effect of PERT on glucose, insulin, GIP, and
GLP-1 profiles after meal. Interestingly, PERT improved the
response of GIP, GLP-1, and insulin response after meal, but
not the postprandial glucose profile [32].
One might, therefore, hypothesize that, also in diabetic
patients with PEI, PERT might ameliorate the postprandial
response of insulinotropic intestinal peptides and subse-
quently the insulin secretion. However, no studies have yet
evaluated the impact of enzymatic replacement on insulin
and incretin levels in response to meal, in these subjects.
Only one prospective study evaluated the effect of PERT
on 39 insulin dependent diabetic (type I or II) patients with
PEI (defined as fecal elastase I concentrations <100 𝜇g/g)
compared to 41 similar patients receiving placebo. This study
showed that PERT improved steatorrhea and malabsorption
symptoms in comparison to the controls receiving placebo
but had no impact on glucose profile, insulin requirement,
and HbA1c levels [17]. However, this study was performed
on a small number of patients for a short period of time
(3 months). Furthermore, all patients with non-insulin-
dependent diabetes and with moderate PEI (fecal elas-
tase concentrations <200𝜇g/g) were excluded, and insulin,
glucagon, and incretin levels, that might be modified by the
enzymatic treatment, were not assessed [17].
Future studies evaluating the influence of PERT on
glycemic control and insulin requirement should enroll
a larger and more homogeneous population of diabetic
patients, with treatment enduring for a longer period of time,
and should also possibly evaluate the relation between PERT
and incretins profile. On the other hand, the potential effect
of treatment with incretins on the exocrine pancreas is also a
controversial area for further research, as the relation between
the exocrine and the endocrine pancreas represents a major
field of investigation [33].
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